[Updated 12:37 p.m.] An experimental Seres Therapeutics capsule of live bacteria has met the goals of a pivotal study evaluating it as a treatment for a type of recurrent gut infection, preliminary results the company says put it on... Read more »
AbbVie has terminated a research partnership with Editas Medicines, returning to the biotech rights to an experimental gene-editing treatment. It’s the second genetic medicines alliance the pharmaceutical company exited this week.
The Editas therapy, EDIT-101, is in Phase 1 testing as... Read more »
The novel coronavirus has driven the pharmaceutical industry to upend its research priorities. Big Pharma companies are focusing on vaccine development and a slew of biotechs are testing compounds, previously intended for a wide range of indications, as potential COVID-19 treatments.... Read more »
It will be difficult to compare Moderna, Inc. and Pfizer Inc.’s coronavirus vaccines based on their Phase 3 study designs, some vaccines experts said.
“Both trials appeared to be well designed,” based on publicly available information, said Ira Longini, co-director of... Read more »
Patients with advanced multiple myeloma have a new treatment option with the FDA’s approval of a GlaxoSmithKline drug that targets B-cell maturation antigen, a protein found on the surface of cancerous plasma cells.
The agency OK’d the London-based pharma giant’s cancer... Read more »
Three early employees of G1 Therapeutics have launched a new oncology-focused company and raised $6 million to move a preclinical program licensed from their former employer into the clinic.
The startup, Research Triangle Park, NC-based Arc Therapeutics, is headed by Patrick... Read more »
Denali Therapeutics has selected a brain-penetrating Parkinson’s disease drug candidate to advance to late-stage testing, and Biogen is paying $1 billion to kick off a partnership on that compound and potentially others.
According to terms of the deal announced Thursday, the... Read more »
One of the challenges facing cell therapy developers is collecting enough cells to produce a viable treatment. It’s a particularly pronounced problem for therapies employing regulatory T cells (Tregs), a type of immune cell that’s relatively scarce in the blood, says... Read more »
CymaBay Therapeutics’ investigational drug seladelpar succeeded in a late-stage trial in patients with primary biliary cholangitis (PBC), producing results that suggest it could have a key side effect advantage compared to a drug currently used to treat the rare liver disease.... Read more »
A partnership between Voyager Therapeutics and AbbVie developing gene therapies for Alzheimer’s and Parkinson’s disease has ended without a drug for either disease reaching human testing.
A MorphoSys antibody drug developed for diffuse large B-cell lymphoma (DLBCL) has won FDA approval, providing an alternative to cumbersome and risky CAR-T therapies to treat the cancer.
The late Friday approval for the drug, tafasitamab (Monjuvi), covers adults whose... Read more »
Another biopharma has signed up to use Sangamo Therapeutics’ gene editing technology to develop therapies that can address disease by heightening or depressing a gene’s activity level.
Public investors are betting big on biotechs, and Inhibrx is looking to capitalize on the industry’s recent resurgence of initial public offerings.
The promise of gene therapies and gene-editing drugs is a long-lasting treatment that’s potentially a cure. But making permanent genetic changes means any accompanying problems could be long-lasting as well, says Omega Therapeutics CEO Mahesh Karande.
Omega is developing technology that... Read more »
Damage to axons, the slender tendrils through which nerve cells communicate, is an early indication of several neurological diseases. Nura Bio, which formed around new research into a mechanism underlying axonal degeneration, made its public debut Wednesday with a $73 million... Read more »
Telemedicine isn’t just another way to connect patients with doctors. AristaMD has carved out a niche in connecting doctors with, well, other doctors.
The San Diego-based telehealth company’s software links primary care physicians and medical specialists through virtual consultations, communication that... Read more »
The lack of diversity in clinical trials is a serious problem that’s persisted for decades. Black Americans—who make up 20 percent of US multiple myeloma patients and are twice as likely to be diagnosed—have only accounted for 4.5 percent of... Read more »
The FDA on Friday approved a Gilead Sciences drug developed for treating mantle cell lymphoma, paving the way for the company to commercialize its second cancer cell therapy.
Approval for the drug, brexucabtagene autoleucel (Tecartus), covers patients whose cancer has relapsed... Read more »